Novo Nordisk: Oddo welcomes study data

(CercleFinance.com) - Oddo BHF maintains its "outperform" rating on Novo Nordisk shares, along with its target price of DKK1,050, after Friday's announcement of clinical data that bodes well for the Oasis 1 trial in obese patients (Rybelsus at the 50mg dose).


The analyst recalls that the Danish laboratory launched two parallel trials to evaluate Rybelsus (already approved at 14mg) at higher doses in patients with type 2 diabetes (PIONEER PLUS) and obese patients (Oasis).

PIONEER PLUS is thus proving positive. The improvement was statistically significant at both doses evaluated with a very good safety profile, it says, adding that this strengthens Novo's offering in type 2 diabetes.


Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.